Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 96.1%

Gross margin was 96.1% in Q1 FY2026, up 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 96.0%, down 0.1 pp year over year. Over 3 fiscal years it narrowed by 0.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
96.1%+0.5 pp QoQ
Last fiscal yearDec 2025
95.9%+0.1 pp YoY
LTMMar 2026
96.0%-0.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.5 pp——
1 year+0.1 pp——
3 years-0.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
95.9%
Year-over-year change
+0.1pp

Gross Margin vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 gross margin of 96.0% is the 2nd highest of the 3 companies compared; the peer median is 89.7%.
  • Its year-over-year change of -0.1 pp is the 2nd highest of 3, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -0.8 pp compares with a peer median of +0.0 pp.
KPTI Competitors Peer median
Gross Margin for KPTI and competitors
Company Period LTM level YoY 3-year change
INMBINmune Bio, Inc.FY2025100.0% +0.0 pp+0.0 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 202696.0% -0.1 pp-0.8 pp
XFORX4 Pharmaceuticals, Inc.LTM Mar 202679.4% -1.2 pp—
TELOTelomir Pharmaceuticals, Inc. Common StockFY2025— ——
Peer median (excluding KPTI) 89.7%-0.6 pp+0.0 pp

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.